CoChat
Sign Up
Cited by 50Medication Adherence and ComplianceCancer survivorship and careBreast Cancer Treatment Studies

A prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving patients’ persistence to adjuvant aromatase inhibitor medication for postmenopausal, early stage breast cancer

Yu, Ke-Da, Zhou, Ying, Liu, Guang-Yu, Li, Bin, He, Ping-Qing, Zhang, Hong-Wei, Lou, Li-Hua, Wang, Xiao-Jia +18 more·2012·Breast Cancer Research and Treatment
DOI 10.1007/s10549-012-2059-8
Open this paper in CoChat — free account

Abstract

Since the rate of persistence to adjuvant endocrine therapy such as 5-year aromatase inhibitors (AI) would decrease over time in patients with hormone-sensitive breast cancer, it is necessary to investigate if a patient support program could modify patients' beliefs and improve their persistence to AI treatment. This was a prospective, multicenter, controlled, observational study to evaluate the efficacy of a patient support program in improving postmenopausal patients' persistence to adjuvant AI medication for early stage breast cancer (NCT00769080). The primary objective was to compare the rates of 1-year persistence to upfront adjuvant AI for patients in the two observational arms (standard treatment group and standard treatment plus patient support program group). In this study, 262 patients were enrolled in the standard treatment group and 241 patients in the standard treatment plus patient support program group. The mean 1-year persistence rates were 95.9 and 95.8% for the standard treatment group and the standard treatment plus patient support program group, respectively (P=0.95). The mean times to treatment discontinuation were 231.2 days in the standard treatment group and 227.8 days in the standard treatment plus patient support program group, with no statistically significant difference between the two groups (P=0.96). There was also no statistically significant difference in the reason for treatment discontinuation (P=0.32). There was a significant relationship between the patient centered care questionnaire and poor persistence (odds ratio=3.9; 95% CI, 1.1-13.7; P=0.035), suggesting that the persistence rate of patients with whom the doctor always or usually spends time is greater than that of patients with whom the doctor sometimes or never spends time. Patients' persistence to adjuvant AI medication for postmenopausal, early stage breast cancer is relatively high in the first year and is not significantly increased by adding a patient support program to standard treatment.

Integrity signals

Registry

Crossref · 10.1007/s10549-012-2059-8

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Yu, K.-D., Zhou, Y., Liu, G.-Y., Li, B., He, P.-Q., Zhang, H.-W., Lou, L.-H., Wang, X.-J., Wang, S., Tang, J.-H., Liu, Y.-H., Wang, X., Jiang, Z.-F., Ma, L.-W., Gu, L., Cao, M.-Z., Zhang, Q.-Y., Wang, S.-M., Su, F.-X., Zheng, H., Li, H.-Y., Tang, L., Sun, S.-R., Liu, J.-P., Shao, Z.-M., & Shen, Z.-Z.
Affiliations
  • Shanghai Medical College of Fudan University (CN)
  • Shanghai Sixth People's Hospital (CN)
  • Fudan University (CN)
  • Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
  • Sun Yat-sen University (CN)
  • Jiangsu Cancer Hospital (CN)
  • Peking University First Hospital (CN)
  • 307th Hospital of Chinese People’s Liberation Army (CN)
  • Peking University Third Hospital (CN)
  • Tianjin Medical University Cancer Institute and Hospital (CN)
  • Qingdao University (CN)
  • Harbin Medical University (CN)
  • Sichuan University (CN)
  • Chongqing Medical University (CN)
  • Xiangya Hospital Central South University (CN)
Corresponding author
Shen, Zhen-Zhou
ORCID
Venue
Breast Cancer Research and Treatment
Publisher
Springer Science and Business Media LLC
Published
2012-04-12
Volume
134
Issue
1
Pages
307-313
ISSN
  • 0167-6806 (ISSN-L)
  • 1573-7217
DOI
10.1007/s10549-012-2059-8
OpenAlex
W2046091735
Cited by
50
References
12
Citations by year
2024: 3 · 2023: 5 · 2022: 10 · 2021: 3 · 2020: 4 · 2019: 5 · 2018: 5 · 2017: 2 · 2016: 3 · 2014: 2 · 2013: 8
FWCI
2.76
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • Breast Cancer Research and Treatment (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
  • Health Sciences › Medicine › Oncology › Cancer survivorship and care
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords
aromatase inhibitors, adjuvant endocrine therapy, treatment persistence, patient support services, early breast cancer, postmenopausal women, treatment discontinuation, patient-centered care, patient beliefs, physician-patient relationship
MeSH terms
Letrozole, Anastrozole, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Breast Neoplasms, Female, Humans, Middle Aged, Neoplasms, Hormone-Dependent, Nitriles, Patient Compliance, Physician-Patient Relations, Practice Patterns, Physicians', Prospective Studies, Surveys and Questionnaires, Triazoles, Chemotherapy, Adjuvant, Postmenopause, Aromatase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review